

# **Blood-Brain Barrier Transport Drugs-Europe Market Status and Trend Report 2013-2023**

<https://marketpublishers.com/r/BEB6418D4E1EN.html>

Date: February 2018

Pages: 142

Price: US\$ 3,480.00 (Single User License)

ID: BEB6418D4E1EN

## **Abstracts**

### **Report Summary**

Blood-Brain Barrier Transport Drugs-Europe Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Blood-Brain Barrier Transport Drugs industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Whole Europe and Regional Market Size of Blood-Brain Barrier Transport Drugs 2013-2017, and development forecast 2018-2023

Main market players of Blood-Brain Barrier Transport Drugs in Europe, with company and product introduction, position in the Blood-Brain Barrier Transport Drugs market  
Market status and development trend of Blood-Brain Barrier Transport Drugs by types and applications

Cost and profit status of Blood-Brain Barrier Transport Drugs, and marketing status  
Market growth drivers and challenges

The report segments the Europe Blood-Brain Barrier Transport Drugs market as:

Europe Blood-Brain Barrier Transport Drugs Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

Germany

United Kingdom

France

Italy

Spain

Benelux

Russia

Europe Blood-Brain Barrier Transport Drugs Market: Product Type Segment Analysis  
(Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Carrier-mediated Transport

Receptor-mediated Transport

Absorptive-mediated Transport

Active Efflux Transport

Others

Europe Blood-Brain Barrier Transport Drugs Market: Application Segment Analysis  
(Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Alzheimer's Disease

Epilepsy

Parkinson's Disease

Multiple Sclerosis

Hunter's Syndrome

Brain Cancer

Others

Europe Blood-Brain Barrier Transport Drugs Market: Players Segment Analysis  
(Company and Product introduction, Blood-Brain Barrier Transport Drugs Sales Volume, Revenue, Price and Gross Margin):

Cyclenium

BioAdvance

EIP Pharma

Bioasis

Immune Pharmaceuticals

AZ Therapies

Palobiofarma

Bach Pharma

BrainsGate  
CarThera  
Dainippon Sumitomo Pharma  
Fluorinov Pharma  
Fondazione Telethon  
Minoryx  
NewGen Therapeutics

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

## Contents

### CHAPTER 1 OVERVIEW OF BLOOD-BRAIN BARRIER TRANSPORT DRUGS

- 1.1 Definition of Blood-Brain Barrier Transport Drugs in This Report
- 1.2 Commercial Types of Blood-Brain Barrier Transport Drugs
  - 1.2.1 Carrier-mediated Transport
  - 1.2.2 Receptor-mediated Transport
  - 1.2.3 Absorptive-mediated Transport
  - 1.2.4 Active Efflux Transport
  - 1.2.5 Others
- 1.3 Downstream Application of Blood-Brain Barrier Transport Drugs
  - 1.3.1 Alzheimer's Disease
  - 1.3.2 Epilepsy
  - 1.3.3 Parkinson's Disease
  - 1.3.4 Multiple Sclerosis
  - 1.3.5 Hunter's Syndrome
  - 1.3.6 Brain Cancer
  - 1.3.7 Others
- 1.4 Development History of Blood-Brain Barrier Transport Drugs
- 1.5 Market Status and Trend of Blood-Brain Barrier Transport Drugs 2013-2023
  - 1.5.1 Europe Blood-Brain Barrier Transport Drugs Market Status and Trend 2013-2023
  - 1.5.2 Regional Blood-Brain Barrier Transport Drugs Market Status and Trend 2013-2023

### CHAPTER 2 EUROPE MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Status of Blood-Brain Barrier Transport Drugs in Europe 2013-2017
- 2.2 Consumption Market of Blood-Brain Barrier Transport Drugs in Europe by Regions
  - 2.2.1 Consumption Volume of Blood-Brain Barrier Transport Drugs in Europe by Regions
  - 2.2.2 Revenue of Blood-Brain Barrier Transport Drugs in Europe by Regions
- 2.3 Market Analysis of Blood-Brain Barrier Transport Drugs in Europe by Regions
  - 2.3.1 Market Analysis of Blood-Brain Barrier Transport Drugs in Germany 2013-2017
  - 2.3.2 Market Analysis of Blood-Brain Barrier Transport Drugs in United Kingdom 2013-2017
  - 2.3.3 Market Analysis of Blood-Brain Barrier Transport Drugs in France 2013-2017
  - 2.3.4 Market Analysis of Blood-Brain Barrier Transport Drugs in Italy 2013-2017
  - 2.3.5 Market Analysis of Blood-Brain Barrier Transport Drugs in Spain 2013-2017

- 2.3.6 Market Analysis of Blood-Brain Barrier Transport Drugs in Benelux 2013-2017
- 2.3.7 Market Analysis of Blood-Brain Barrier Transport Drugs in Russia 2013-2017
- 2.4 Market Development Forecast of Blood-Brain Barrier Transport Drugs in Europe 2018-2023
  - 2.4.1 Market Development Forecast of Blood-Brain Barrier Transport Drugs in Europe 2018-2023
  - 2.4.2 Market Development Forecast of Blood-Brain Barrier Transport Drugs by Regions 2018-2023

## **CHAPTER 3 EUROPE MARKET STATUS AND FORECAST BY TYPES**

- 3.1 Whole Europe Market Status by Types
  - 3.1.1 Consumption Volume of Blood-Brain Barrier Transport Drugs in Europe by Types
  - 3.1.2 Revenue of Blood-Brain Barrier Transport Drugs in Europe by Types
- 3.2 Europe Market Status by Types in Major Countries
  - 3.2.1 Market Status by Types in Germany
  - 3.2.2 Market Status by Types in United Kingdom
  - 3.2.3 Market Status by Types in France
  - 3.2.4 Market Status by Types in Italy
  - 3.2.5 Market Status by Types in Spain
  - 3.2.6 Market Status by Types in Benelux
  - 3.2.7 Market Status by Types in Russia
- 3.3 Market Forecast of Blood-Brain Barrier Transport Drugs in Europe by Types

## **CHAPTER 4 EUROPE MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY**

- 4.1 Demand Volume of Blood-Brain Barrier Transport Drugs in Europe by Downstream Industry
- 4.2 Demand Volume of Blood-Brain Barrier Transport Drugs by Downstream Industry in Major Countries
  - 4.2.1 Demand Volume of Blood-Brain Barrier Transport Drugs by Downstream Industry in Germany
  - 4.2.2 Demand Volume of Blood-Brain Barrier Transport Drugs by Downstream Industry in United Kingdom
  - 4.2.3 Demand Volume of Blood-Brain Barrier Transport Drugs by Downstream Industry in France
  - 4.2.4 Demand Volume of Blood-Brain Barrier Transport Drugs by Downstream Industry in Italy

4.2.5 Demand Volume of Blood-Brain Barrier Transport Drugs by Downstream Industry in Spain

4.2.6 Demand Volume of Blood-Brain Barrier Transport Drugs by Downstream Industry in Benelux

4.2.7 Demand Volume of Blood-Brain Barrier Transport Drugs by Downstream Industry in Russia

4.3 Market Forecast of Blood-Brain Barrier Transport Drugs in Europe by Downstream Industry

## **CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF BLOOD-BRAIN BARRIER TRANSPORT DRUGS**

5.1 Europe Economy Situation and Trend Overview

5.2 Blood-Brain Barrier Transport Drugs Downstream Industry Situation and Trend Overview

## **CHAPTER 6 BLOOD-BRAIN BARRIER TRANSPORT DRUGS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EUROPE**

6.1 Sales Volume of Blood-Brain Barrier Transport Drugs in Europe by Major Players

6.2 Revenue of Blood-Brain Barrier Transport Drugs in Europe by Major Players

6.3 Basic Information of Blood-Brain Barrier Transport Drugs by Major Players

6.3.1 Headquarters Location and Established Time of Blood-Brain Barrier Transport Drugs Major Players

6.3.2 Employees and Revenue Level of Blood-Brain Barrier Transport Drugs Major Players

6.4 Market Competition News and Trend

6.4.1 Merger, Consolidation or Acquisition News

6.4.2 Investment or Disinvestment News

6.4.3 New Product Development and Launch

## **CHAPTER 7 BLOOD-BRAIN BARRIER TRANSPORT DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA**

7.1 Cyclenium

7.1.1 Company profile

7.1.2 Representative Blood-Brain Barrier Transport Drugs Product

7.1.3 Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin of Cyclenium

## 7.2 BioAdvance

### 7.2.1 Company profile

### 7.2.2 Representative Blood-Brain Barrier Transport Drugs Product

### 7.2.3 Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin of BioAdvance

## 7.3 EIP Pharma

### 7.3.1 Company profile

### 7.3.2 Representative Blood-Brain Barrier Transport Drugs Product

### 7.3.3 Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin of EIP Pharma

## 7.4 Bioasis

### 7.4.1 Company profile

### 7.4.2 Representative Blood-Brain Barrier Transport Drugs Product

### 7.4.3 Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin of Bioasis

## 7.5 Immune Pharmaceuticals

### 7.5.1 Company profile

### 7.5.2 Representative Blood-Brain Barrier Transport Drugs Product

### 7.5.3 Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin of Immune Pharmaceuticals

## 7.6 AZ Therapies

### 7.6.1 Company profile

### 7.6.2 Representative Blood-Brain Barrier Transport Drugs Product

### 7.6.3 Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin of AZ Therapies

## 7.7 Palobiofarma

### 7.7.1 Company profile

### 7.7.2 Representative Blood-Brain Barrier Transport Drugs Product

### 7.7.3 Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin of Palobiofarma

## 7.8 Bach Pharma

### 7.8.1 Company profile

### 7.8.2 Representative Blood-Brain Barrier Transport Drugs Product

### 7.8.3 Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin of Bach Pharma

## 7.9 BrainsGate

### 7.9.1 Company profile

### 7.9.2 Representative Blood-Brain Barrier Transport Drugs Product

### 7.9.3 Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin of

## BrainsGate

### 7.10 CarThera

#### 7.10.1 Company profile

#### 7.10.2 Representative Blood-Brain Barrier Transport Drugs Product

#### 7.10.3 Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin of CarThera

### 7.11 Dainippon Sumitomo Pharma

#### 7.11.1 Company profile

#### 7.11.2 Representative Blood-Brain Barrier Transport Drugs Product

#### 7.11.3 Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin of Dainippon Sumitomo Pharma

### 7.12 Fluorinov Pharma

#### 7.12.1 Company profile

#### 7.12.2 Representative Blood-Brain Barrier Transport Drugs Product

#### 7.12.3 Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin of Fluorinov Pharma

### 7.13 Fondazione Telethon

#### 7.13.1 Company profile

#### 7.13.2 Representative Blood-Brain Barrier Transport Drugs Product

#### 7.13.3 Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin of Fondazione Telethon

### 7.14 Minoryx

#### 7.14.1 Company profile

#### 7.14.2 Representative Blood-Brain Barrier Transport Drugs Product

#### 7.14.3 Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin of Minoryx

### 7.15 NewGen Therapeutics

#### 7.15.1 Company profile

#### 7.15.2 Representative Blood-Brain Barrier Transport Drugs Product

#### 7.15.3 Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin of NewGen Therapeutics

## **CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF BLOOD-BRAIN BARRIER TRANSPORT DRUGS**

### 8.1 Industry Chain of Blood-Brain Barrier Transport Drugs

### 8.2 Upstream Market and Representative Companies Analysis

### 8.3 Downstream Market and Representative Companies Analysis



## **CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF BLOOD-BRAIN BARRIER TRANSPORT DRUGS**

- 9.1 Cost Structure Analysis of Blood-Brain Barrier Transport Drugs
- 9.2 Raw Materials Cost Analysis of Blood-Brain Barrier Transport Drugs
- 9.3 Labor Cost Analysis of Blood-Brain Barrier Transport Drugs
- 9.4 Manufacturing Expenses Analysis of Blood-Brain Barrier Transport Drugs

## **CHAPTER 10 MARKETING STATUS ANALYSIS OF BLOOD-BRAIN BARRIER TRANSPORT DRUGS**

- 10.1 Marketing Channel
  - 10.1.1 Direct Marketing
  - 10.1.2 Indirect Marketing
  - 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
  - 10.2.1 Pricing Strategy
  - 10.2.2 Brand Strategy
  - 10.2.3 Target Client
- 10.3 Distributors/Traders List

## **CHAPTER 11 REPORT CONCLUSION**

## **CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE**

- 12.1 Methodology/Research Approach
  - 12.1.1 Research Programs/Design
  - 12.1.2 Market Size Estimation
  - 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source
  - 12.2.1 Secondary Sources
  - 12.2.2 Primary Sources
- 12.3 Reference

## I would like to order

Product name: Blood-Brain Barrier Transport Drugs-Europe Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/BEB6418D4E1EN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/BEB6418D4E1EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970